BACKGROUND
Brilliant blue G (BBG) is a
P2X7 receptor inhibitor that has been reported to improve
spinal cord injury (SCI) in previous studies, but the specific mechanism has been unclear. In this study, we investigated the effects of BBG on
inflammasomes and blood-spinal cord barrier (BSCB) permeability after SCI. MATERIAL AND METHODS The experimental rats were randomly divided into 3 groups:
sham, SCI, and SCI+BBG. The expression of P2X7 and
inflammasome-related
proteins was measured by Western blot and immunohistochemistry, while IL-1ß and
IL-18 levels were measured by using an
enzyme-linked
immunosorbent assay (ELISA) kit. The permeability of the BSCB was evaluated by
Evans Blue (EB) exosmosis, and histological alterations were observed by
hematoxylin-
eosin staining. Motor function recovery was assessed by the Basso, Beattie, Bresnahan (BBB) scale after SCI. RESULTS The expression levels of P2X7, NLRP3, ASC, cleaved XIAP, caspase-1, caspase-11, IL-1ß, and
IL-18 were increased significantly after SCI, and BBG administration inhibited this increase at 72 h after SCI. BBG administration significantly reduced EB leakage at 24 h after SCI. Furthermore, treatment with BBG significantly attenuated histological alterations and improved motor function recovery after SCI. CONCLUSIONS BBG administration promoted motor function recovery and alleviated tissue injury, and these effects might be related to the suppression of
inflammasomes and the maintenance of BSCB integrity.